Breast Cancer

FDA Clearance Announced Blood Test to Aid in Managing Metastatic Cancer

Published in Blood Weekly, September 8th, 1997

Chiron Diagnostics, East Walpole, Massachusetts, a business unit of Chiron Corp., announced the U.S. launch of ACS:180 BR, a blood test for the breast cancer antigen CA 27.29.

The test received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is available in the U.S. to physicians to monitor their patients with metastatic breast cancer.

Chiron Diagnostics' ACS:180 BR is intended for use as an aid in the management of breast cancer patients with metastatic disease. The test allows clinicians to monitor the cancer's progression or regression in response to treatment. ACS:180 BR is an in vitro diagnostic test for the quantitative...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry